Cytokinetics supports a three-year American Heart Association initiative to improve care for hypertrophic cardiomyopathy patients.
Quiver AI Summary
Cytokinetics, Inc. announced its support for a three-year initiative led by the American Heart Association aimed at improving care, diagnosis, and treatment access for individuals with hypertrophic cardiomyopathy (HCM), a commonly inherited but often underdiagnosed heart disease. The initiative seeks to address disparities in healthcare delivery, as many patients face delays in diagnosis and treatment. Cytokinetics will contribute to efforts including expanding a national HCM Registry, offering certification opportunities for healthcare providers, and implementing support services at diagnosis and treatment centers. This collaboration is part of Cytokinetics' broader commitment to enhance care for HCM patients and reflects its ongoing involvement in cardiovascular research and advocacy.
Potential Positives
- Cytokinetics is actively supporting a three-year initiative led by the American Heart Association to improve care for patients with hypertrophic cardiomyopathy (HCM), addressing significant healthcare disparities.
- The company’s participation reinforces its commitment to the HCM community and aligns with its patient-centric culture, highlighting its dedication to elevating the standard of care for heart disease.
- This initiative aims to reduce underdiagnosis and improve access to specialty care for HCM patients, potentially enhancing treatment outcomes and patient quality of life.
- Cytokinetics is preparing for potential regulatory approvals of its investigational therapies for HCM, which positions the company favorably in a market with urgent unmet medical needs.
Potential Negatives
- Cytokinetics is involved in a lengthy initiative aimed at addressing significant disparities in healthcare access and treatment for HCM, indicating potential prior shortcomings in their approach to patient care.
- The press release emphasizes a multi-stakeholder initiative, which may suggest that Cytokinetics recognizes existing gaps in its own capabilities and may rely on external organizations to improve care.
- The mention of investigational medicines not yet approved by regulatory agencies raises questions about the timing and efficacy of their product pipeline, which could impact investor confidence.
FAQ
What is the initiative supported by Cytokinetics?
Cytokinetics supports a three-year initiative by the American Heart Association to improve care for hypertrophic cardiomyopathy (HCM) patients.
How does Cytokinetics contribute to HCM care?
Cytokinetics offers its expertise and resources to address gaps in diagnosis, treatment, and access for patients with HCM.
Why is HCM often underdiagnosed?
Hypertrophic cardiomyopathy is frequently underdiagnosed due to lack of awareness, leading to delayed diagnoses and limited access to care.
What are the goals of the HCM initiative?
The initiative aims to improve identification, assessment, referral, and treatment processes for individuals living with HCM.
Where can I find more information about Cytokinetics’ HCM efforts?
Additional information about Cytokinetics’ commitment to the HCM community is available on their website at www.cytokinetics.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 11 sales selling 55,000 shares for an estimated $2,440,300.
- EDWARD M. MD KAYE has made 0 purchases and 5 sales selling 29,019 shares for an estimated $1,565,485.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 12 sales selling 24,400 shares for an estimated $1,066,780.
- ANDREW CALLOS (EVP, Chief Commercial Officer) sold 8,659 shares for an estimated $277,434
- WENDELL WIERENGA sold 4,375 shares for an estimated $256,725
- ROBERT ARTHUR HARRINGTON sold 2,150 shares for an estimated $104,640
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 227 institutional investors add shares of $CYTK stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 2,250,000 shares (-75.6%) from their portfolio in Q3 2025, for an estimated $123,660,000
- FMR LLC added 1,824,136 shares (+16.2%) to their portfolio in Q3 2025, for an estimated $100,254,514
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,478,056 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $81,233,957
- WOODLINE PARTNERS LP added 1,435,422 shares (+676.1%) to their portfolio in Q3 2025, for an estimated $78,890,793
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,310,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,293,501
- UBS GROUP AG removed 1,267,414 shares (-41.3%) from their portfolio in Q3 2025, for an estimated $69,657,073
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,256,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,517,403
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CYTK Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 11/10/2025
- Barclays issued a "Overweight" rating on 10/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
- JMP Securities issued a "Market Outperform" rating on 09/02/2025
- Citigroup issued a "Buy" rating on 09/02/2025
- Stifel issued a "Buy" rating on 09/02/2025
- Needham issued a "Buy" rating on 09/02/2025
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 12 analysts offer price targets for $CYTK in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $87.0 on 11/11/2025
- Mayank Mamtani from B. Riley Securities set a target price of $90.0 on 11/10/2025
- Gena Wang from Barclays set a target price of $82.0 on 10/06/2025
- Jason Zemansky from B of A Securities set a target price of $56.0 on 10/02/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $120.0 on 09/29/2025
- Cory Kasimov from Evercore ISI Group set a target price of $80.0 on 09/03/2025
- Serge Belanger from Needham set a target price of $72.0 on 09/02/2025
Full Release
System of Care to Advance Care for the Most Commonly Inherited Heart Disease
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.
“Too many patients living with HCM face a lack of awareness about their condition, delayed diagnoses, and limited access to specialty care,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are proud to support the American Heart Association to advance a more standardized and comprehensive system of care. This important initiative aligns with our science and patient-centric company culture and reinforces our commitment to elevate the standard of care for those living with HCM.”
An estimated one in 500 people in the U.S. are living with HCM but many remain undiagnosed or untreated until acute symptoms occur. This underdiagnosis has led to inconsistent and fragmented systems of care. The American Heart Association initiative seeks to identify systemic barriers to improve HCM systems of care and improve how patients with HCM are identified, assessed, referred, and treated.
Cytokinetics’ support will build on a national effort to unify and elevate care for HCM patients by:
- increasing the number of sites participating in a national HCM Registry powered by Get With The Guidelines ® ;
- broadening certification opportunities for referring centers and personnel to reach more communities and patients;
- introducing patient support services at key HCM diagnosis and treatment centers; and
- implementing a prospective pilot of the Association’s HCM detection algorithm designed to reduce underdiagnosis.
“Cytokinetics’ participation underscores the importance of working across sectors to advance heart health,” said Anjali Owens, M.D., co-chair of the American Heart Association’s HCM initiative. “HCM is often inconsistently managed, leading to delayed treatment, increased risk of complications and preventable death. With this added support, we will work to drive meaningful change that empowers patients, informs clinicians, and strengthens the care continuum for HCM.”
Cytokinetics has been at the forefront of HCM-related research and advocacy activities. In addition to its investigational therapies for HCM and other cardiovascular conditions, the company actively collaborates with patient advocacy organizations, clinicians, and policymakers to enhance disease awareness and improve care pathways.
To learn more about Cytokinetics’ commitment to the HCM community, visit www.cytokinetics.com . To learn more about the initiative, visit www.heart.org/HCMregistry .
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten , a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten , a cardiac myosin inhibitor with a mechanism of action distinct from aficamten , for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .
Disclaimer
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
